Braingaze develops diagnostic and therapeutic products that combine patented biomarkers of ocular micromovements, casual video games, and deep-learning algorithms. Its diagnostic solutions aim to deliver cutting-edge accuracy and objectivity for conditions such as ADHD, Alzheimer’s disease, and autism spectrum disorder. The company’s therapeutic offering, including BGaze Therapy — an eye-movement attention-training game — has been tested in clinics and shown promising improvements in cognitive function beyond behavioral training, reportedly mimicking pharmacological effects without side effects. Braingaze’s ADHD diagnostic tools have been used in clinical practice in Spain by pioneering physicians in Madrid and Barcelona. The company plans to use the new funding to accelerate clinical and commercial development, launch clinical solutions, and expand access to consumers via mobile platforms. CEO Laszlo Bax said the team is focused on executing the milestones ahead and growing multi-market business traction. Braingaze develops next-generation eye-tracking software that predicts and identifies personal behaviour for clinical and commercial applications. The company is building several applications, including tools for diagnosing ADHD, analysing consumer preference, and aiding video game navigation. New funding will be used primarily for R&D, product development, patent expansion, regulatory compliance, and to develop a clinical trial programme in Europe and the US. Braingaze recently secured €336K of public and private capital in its first pre-seed round. The seven-person team has moved into larger offices within the Tecnocampus Mataró incubator near Barcelona. Founders Laszlo Bax and Hans Super also increased their investment at the same valuation offered to new investors.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2024